Debt-to-equity of Acrivon Therapeutics, Inc. from 30 Jun 2023 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Acrivon Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2023 to 30 Sep 2025.
Acrivon Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 11%, a 16% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Acrivon Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	11%	+1.5%	+16%	30 Sep 2025
Q2 2025	10%	+0.42%	+4.3%	30 Jun 2025
Q1 2025	9.1%	-1.3%	-12%	31 Mar 2025
Q4 2024	9.3%	+0.37%	+4.2%	31 Dec 2024
Q3 2024	9.6%	+2.5%	+35%	30 Sep 2024
Q2 2024	9.8%	+0.08%	+0.82%	30 Jun 2024
Q1 2024	10%			31 Mar 2024
Q4 2023	8.9%			31 Dec 2023
Q3 2023	7.2%			30 Sep 2023
Q2 2023	9.7%			30 Jun 2023

* An asterisk sign (*) next to the value indicates that the value is likely invalid.